PSODEEP2 Pilot Study on Koebner Induction in Psoriasis
Launched by SKANE UNIVERSITY HOSPITAL · May 13, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The PSODEEP2 Pilot Study is a research trial looking at a specific reaction in people with psoriasis called the Koebner phenomenon. This happens when new psoriasis patches develop on skin that has been injured or stressed. The study will include 15 adult participants who have been diagnosed with skin psoriasis and have reported experiencing this reaction. To be eligible, participants must not be receiving any systemic treatments, which are medications that affect the entire body, including certain types of light therapy.
If you decide to participate in this study, you will be asked to undergo a procedure on your arms and legs to see how your skin reacts to an induced injury. This may help researchers better understand psoriasis and how it behaves. It’s important to know that the study is not yet recruiting participants, but it is open to anyone aged 18 or older who meets the criteria. Your involvement could contribute to valuable insights into managing this skin condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Self reported Koebner
- • Diagnosis of skin psoriasis
- Exclusion Criteria:
- • Systemic immunomodulatory treatment (including narrowband UVB)
About Skane University Hospital
Skåne University Hospital is a leading academic medical center located in Sweden, renowned for its commitment to advancing healthcare through innovative clinical research and trials. As a key player in the Nordic healthcare landscape, the hospital integrates cutting-edge medical practices with rigorous scientific inquiry, aiming to improve patient outcomes and foster advancements in medical knowledge. With a multidisciplinary approach, Skåne University Hospital collaborates with various stakeholders, including universities and research institutions, to conduct high-quality clinical trials that address critical health challenges and contribute to the development of new treatments and therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Liv Eidsmo, Professor
Study Director
Copenhagen University SIC, Karolinska Institutet
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported